ZLAB FY2025 SEC EDGAR DEF 14A #167 of 168 in industry

Zai Lab Ltd CEO pay ratio

The CEO earned $10.7M in FY2025 against median worker pay of $70,126 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
E9
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#167/168

Data updated August 2026

Subscribe to Zai Lab Ltd CEO pay filing updates (RSS)

CEO-to-worker pay ratio
1:1
Below Average (Scale: 0–1000:1)
CEO pay
$10.7M
Median worker
$70,126

Answer first

Zai Lab Ltd's FY2025 CEO total of $10.7M ranks #488 of 1,423 complete filings; its 1:1 pay ratio ranks #1416. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $70,126. Industry placement uses the FY2025 SIC-28 peer cohort (# 167 of 168, 1st percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#488
$10.7M of 1,423 FY2025
Ratio rank
#1416
1:1 of 1,423
Industry pct
1st
among the lower quartile of industry peers by pay ratio

How Zai Lab Ltd ranks nationally

Zai Lab Ltd CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$10,677,221 Top 34% higher than 66% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). This entry sits in this band. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Zai Lab Ltd vs. Chemicals & Pharmaceuticals peers

CEO total pay ($10.7M) against pay ratio (1:1) for Zai Lab Ltd (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02798065.35596130.68394195.911192261.30:111.0:122.0:133.0:144.0:1CEO total payPay ratio (CEO : median worker)Zai Lab Ltd, CEO total pay: 10677221 · Pay ratio (CEO : median worker): 1:1Zai Lab LtdVanda Pharmaceuticals Inc., CEO total pay: 3851468 · Pay ratio (CEO : median worker): 1:1Vanda Pharmaceuticals Inc.Spyre Therapeutics, Inc., CEO total pay: 437242 · Pay ratio (CEO : median worker): 1:1Spyre Therapeutics, Inc.Twist Bioscience Corp, CEO total pay: 376416 · Pay ratio (CEO : median worker): 2:1Twist Bioscience CorpSummit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.
Zai Lab Ltd vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Zai Lab Ltd's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Zai Lab Ltd

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
1:1
FY2025
vs prior FY
0:1
from FY2024 1:1
CEO $ YoY
+18%
$10.7M latest
Filings shown
5
FY2021–2025
Zai Lab Ltd CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $95K - $94,930 1:1 -
2022 $20.2M +21192% $106,671 1:1 0:1
2023 $12.0M -40% $86,709 1:1 0:1
2024 $9.1M -25% $70,620 1:1 0:1
2025 $10.7M +18% $70,126 1:1 0:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1704292, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
1:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.7M
Companies in Industry
168
vs. Industry Median
Below
#167 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Zai Lab Ltd: near-parity Item 402(u) ratio

Zai Lab Ltd's FY2025 ratio 1:1 ranks #167 of 168 Chemicals & Pharmaceuticals filers (1st percentile). the CEO earned 1× the median employee ($70,126) in FY2025.

At $70,126 median worker pay, the PARITY stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$10.7M

FY2025 Summary Compensation, above median

Pay Ratio

1:1

Below typical

Zai Lab Ltd in the lower Chemicals & Pharmaceuticals third

Zai Lab Ltd's FY2025 ratio 1:1 ranks #167 of 168 Chemicals & Pharmaceuticals filers (1st percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Zai Lab Ltd's $10.7M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #488 and ratio rank #1416 split - treat 1:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$10.7M
Median Employee Pay
$70,126
Pay Ratio
1:1
Filing Date
2026-04-28

Company Info

Ticker
ZLAB
CIK
1704292
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
E9
View SEC filings →
SEC EDGAR DEF 14A for CIK 1704292, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Zai Lab Ltd's FY2025 ratio 1:1 ranks #167 of 168 Chemicals & Pharmaceuticals filers (1st percentile).

Read with Zai Lab Ltd

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps PARITY · HEAVY · HIGH-MED.

Amn Healthcare Services Inc · HEAVY

ABS(ceo_total_comp) peer at $10.7M (Δ $7K lighter vs Zai Lab Ltd); MID · HIGH-MED vs this page's PARITY · HEAVY · HIGH-MED.
Toast, Inc. · HEAVY

ABS(ceo_total_comp) peer at $10.7M (Δ $9K lighter vs Zai Lab Ltd); MID · ELITE-MED vs this page's PARITY · HEAVY · HIGH-MED.
Floor & Decor Holdings, Inc. · HEAVY

ABS(ceo_total_comp) peer at $10.7M (Δ $10K lighter vs Zai Lab Ltd); HIGH · LOW-MED vs this page's PARITY · HEAVY · HIGH-MED.
LifeStance Health Group, Inc. · HEAVY

ABS(ceo_total_comp) peer at $10.7M (Δ $15K heavier vs Zai Lab Ltd); MID · HIGH-MED vs this page's PARITY · HEAVY · HIGH-MED.
Vanda Pharmaceuticals Inc. (SIC 28 pole)

Vanda Pharmaceuticals Inc. stamps PARITY · MID$ nearest in-SIC by ABS(pay_ratio) to Zai Lab Ltd's PARITY filing.
National dual ranks · #488/#1416

Zai Lab Ltd's FY2025 package sits #488 by CEO dollars and #1416 by ratio under HEAVY · PARITY.
Ratio primer · PARITY

Zai Lab Ltd's PARITY stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Zai Lab Ltd (CIK 1704292), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.